Press Releases - Infectious Disease

Press Releases - Infectious Disease

October 06, 2020
$18.2 million in Phase 2 funding will support the development and scale-up of COVID-19 antigen test based on Simoa® technology  
October 05, 2020
BILLERICA, Mass.--(BUSINESS WIRE)--Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis to advance the science of precision health, today announced it has entered into a non-exclusive royalty-bearing license agreement with Abbot
July 20, 2020
Findings from newly published research demonstrate promise of ultra-sensitive biomarker technology to identify and define high-risk populations through quantification of interferon (IFN) type I
May 11, 2020
Test deployed on Quanterix' Ultrasensitive Simoa® platform improves sensitivity and specificity for measuring immune response and seroconversion earlier and with higher resolution
April 24, 2020
Grants will award researchers seeking to harness biomarkers to improve diagnosis, prognosis or treatment efficacy studies with access to Quanterix’ ultra-sensitive detection solutions

This website uses cookies. By continuing to use this website you are acknowledging and agree with our cookie policy.

AgreeLearn more